• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

BVI launches PODEYE hydrophobic monofocal IOL in Japan


The IOL launch is the company’s second market debut in less than 12 months.

Intraocular lens taken out of injector Image Credit: AdobeStock/Oktay

Image Credit: AdobeStock/Oktay

BVI has made its second market debut in less than 12 months with its official launch of the PODEYE hydrophobic monofocal intraocular lens (IOL) in Japan, a country known for its hydrophobic market. The new product had been approved by the Japanese Pharmaceuticals and Medical Devices Agency and is now available for commercial use and surgeons, according to a news release. The IOL was unveiled during the Japanese Ophthalmological Society annual meeting in Tokyo, Japan, held from April 18 to 21.1,2

“Our commitment to the Japanese ophthalmic market is a clear priority for BVI. The PODEYE launch continues to execute on our strategic vision and global expansion. We are set to equip surgeons with more solutions to enhance patient care. Anticipate more groundbreaking product launches from us in Japan and many other major markets globally.” said Shervin Korangy, president and CEO of BVI.

The IOL utilizes double C-loop haptic design that is unique to BVI lenses and referred to as “POD.” Additionally, the IOL’s proprietary, hydrophobic GFY material is also specific to BVI, which provides 100% glistening-free material. The POD design was introduced with the launch of the PODEYE hydrophobic IOL in Europe in 2012. The double C-loop design has proven successful with reliable IOL centration and rotational stability, according to the release.

Currently, BVI develops and supplies approximately 20% of IOL material for competing IOL companies global.1 The company’s IPure IOLs are available in B1PC (clear), B1PY (yellow), and B3PC (clear).3 Each type of IOL has high contrast in various lighting conditions and maintains natural corneal depth of focus. IPURE IOLs also have faster average IOL prep and delivery time in comparison to manually loaded IOL delivery systems, according to BVI.3

  1. BVI launches PODEYE hydrophobic monofocal IOL in Japan. News release. BVI. April 18, 2024. Accessed April 23, 2024. https://www.bvimedical.com/us/bvi-launches-podeye-hydrophobic-monofocal-iol-in-japan/
  2. The 128th annual meeting of the Japanese Ophthalmological Society, Department of Ophthalmology, Shinshu University School of Medicine. Japanese Ophthalmological Society. Accessed April 22, 2024. https://www.congre.co.jp/jos2024/en/index.html
  3. IPure Intraocular lenses. BVI. Accessed April 23, 2024. https://www.bvimedical.com/us/intraocular-lenses/ 
Related Videos
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
© 2024 MJH Life Sciences

All rights reserved.